Fibronectin degradation as biomarker for Trypanosoma cruzi infection and treatment monitoring in mice

Biomarkers (coming from host or parasite) to monitor Chagas disease (CD) progression as well as the therapeutic response in chronic CD are critically needed, since seronegativization, which may be considered the best indicator of therapeutic cure, takes several years to be observed in adults. Severa...

Full description

Saved in:
Bibliographic Details
Published in:Parasitology 2021-08, Vol.148 (9), p.1067-1073
Main Authors: Hernández-Cuevas, Nora Adriana, Marín-Cervera, Andrea, Garcia-Polanco, Shineily, Martínez-Vega, Pedro, Rosado-Vallado, Miguel, Dumonteil, Eric
Format: Article
Language:English
Subjects:
Animal models
Animals
Antibodies
Benznidazole
Biomarkers
Chagas disease
Chagas Disease - diagnosis
Chagas Disease - parasitology
Chronic infection
Degradation
Drug dosages
Fibronectin
Fibronectins - blood
Infections
Inflammation
Metabolism
Mice
Mice, Inbred BALB C
Mice, Inbred ICR
Parasitemia - diagnosis
Parasitemia - parasitology
Parasites
Parasitic diseases
Plasma
Proteins
Protozoa
Trypanosoma cruzi
Trypanosoma cruzi - isolation & purification
Vaccination
Vaccines
Vector-borne diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Biomarkers (coming from host or parasite) to monitor Chagas disease (CD) progression as well as the therapeutic response in chronic CD are critically needed, since seronegativization, which may be considered the best indicator of therapeutic cure, takes several years to be observed in adults. Several molecules have been suggested as biomarkers for CD, however, they have to be validated. Taking advantage of mouse models of Trypanosoma cruzi infection, we investigated changes in the degradation profile of fibronectin in plasma. The degradation profile of fibronectin was different in the acute phase compared to the chronic phase of the infection. Fibronectin fragments of approximately 150, 100, 40 and 30 kDa were identified. Furthermore, those degradation profiles correlated with acute parasitaemia as well as with cardiac parasite burden and tissue damage during the infection. The usefulness of fibronectin degradation as a biomarker for therapeutic response following drug treatment and immunotherapeutic vaccination also was evaluated and a decreased fibronectin degradation profile was observed upon benznidazole or a vaccine candidate treatment.
ISSN:0031-1820
1469-8161
1469-8161
DOI:10.1017/S0031182021000809